Incyte Corporation NASDAQ:INCY

Incyte stock price today

$85.46
+16.22
+23.44%
Financial Health
0
1
2
3
4
5
6
7
8
9

Incyte stock price monthly change

+8.75%
month

Incyte stock price quarterly change

+8.75%
quarter

Incyte stock price yearly change

+10.45%
year

Incyte key metrics

Market Cap
13.21B
Enterprise value
13.43B
P/E
47.54
EV/Sales
3.95
EV/EBITDA
22.39
Price/Sales
4.81
Price/Book
3.74
PEG ratio
-0.74
EPS
3.33
Revenue
3.76B
EBITDA
958.42M
Income
745.44M
Revenue Q/Q
8.93%
Revenue Y/Y
8.58%
Profit margin
10.04%
Oper. margin
17.07%
Gross margin
93.9%
EBIT margin
17.07%
EBITDA margin
25.44%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Incyte stock price history

Incyte stock forecast

Incyte financial statements

Average Price Target
Last Year

$92.3

Potential upside: 8.00%

Based on estimate of 8 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Incyte Corporation (NASDAQ:INCY): Profit margin
Jun 2023 954.61M 203.54M 21.32%
Sep 2023 919.02M 171.26M 18.64%
Dec 2023 1.01B 201.07M 19.84%
Mar 2024 880.88M 169.54M 19.25%
Incyte Corporation (NASDAQ:INCY): Debt to assets
Jun 2023 6208259000 1.46B 23.64%
Sep 2023 6388239000 1.45B 22.8%
Dec 2023 6782107000 1.59B 23.48%
Mar 2024 7135605000 1.74B 24.4%
Incyte Corporation (NASDAQ:INCY): Cash Flow
Jun 2023 306.52M -7.42M 12.86M
Sep 2023 147.83M -17.18M -37.25M
Dec 2023 147.72M -154.5M 346K
Mar 2024 218.81M -73.11M -12.41M

Incyte alternative data

Incyte Products

Incyte Corporation (NASDAQ:INCY): Google Trends - Incyte Products
19 Feb 2023 61190
26 Feb 2023 602140
5 Mar 2023 501111
12 Mar 2023 500110
19 Mar 2023 601121
26 Mar 2023 511120
2 Apr 2023 412122
9 Apr 2023 622131
16 Apr 2023 61270
23 Apr 2023 601110
30 Apr 2023 511130
7 May 2023 702111
14 May 2023 520120
21 May 2023 501101
28 May 2023 401130
4 Jun 2023 722100
11 Jun 2023 601121
18 Jun 2023 50191
25 Jun 2023 500112
2 Jul 2023 412110

Numbers represent search interest relative to the highest point on the chart for the given region and time.

A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.

Incyte Corporation (NASDAQ:INCY): Job openings
Aug 2023 52
Sep 2023 61
Oct 2023 62
Nov 2023 48
Dec 2023 42
Jan 2024 47
Feb 2024 49
Apr 2024 71
May 2024 78
Jun 2024 83
Jul 2024 64
Dec 2024 70
Jan 2025 76
Feb 2025 111
May 2025 119
Jul 2025 116
Aug 2025 101
Incyte Corporation (NASDAQ:INCY): Employee count
Aug 2023 2,324
Sep 2023 2,324
Oct 2023 2,324
Nov 2023 2,324
Dec 2023 2,324
Jan 2024 2,324
Feb 2024 2,324
Mar 2024 2,524
Apr 2024 2,524
May 2024 2,524
Jun 2024 2,524
Jul 2024 2,524

Incyte other data

91.83% +0.80%
of INCY is owned by hedge funds
203.92M +1.62M
shares is hold by hedge funds

Incyte Corporation (NASDAQ:INCY): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 8022
Jun 2024 0 20257
Jul 2024 0 25025
Aug 2024 0 11608
Sep 2024 0 9404
Nov 2024 0 9723
Dec 2024 0 1300
Transaction Date Insider Security Shares Price per share Total value Source
Sale
TRAY THOMAS officer: Principal Accounting O..
Common Stock 650 $69.31 $45,052
Sale
TRAY THOMAS officer: Principal Accounting O..
Common Stock 650 $70.64 $45,916
Sale
IYENGAR VIJAY K officer: EVP, GMA.. Common Stock 360 $75.6 $27,216
Sale
IYENGAR VIJAY K officer: EVP, GMA.. Common Stock 5,683 $75.37 $428,328
Option
FLANNELLY BARRY P officer: EVP & General Manager US
Common Stock 2,256 $68.62 $154,807
Sale
FLANNELLY BARRY P officer: EVP & General Manager US
Common Stock 1,424 $82 $116,768
Option
FLANNELLY BARRY P officer: EVP & General Manager US
Common Stock 1,424 $72.27 $102,912
Sale
FLANNELLY BARRY P officer: EVP & General Manager US
Common Stock 2,256 $78.21 $176,442
Option
FLANNELLY BARRY P officer: EVP & General Manager US
Employee Stock Option (right to buy) 3,680 $70.45 $259,238
Sale
TRAY THOMAS officer: Principal Accounting O..
Common Stock 382 $63.37 $24,207
Patent
Application
Filling date: 28 Mar 2022 Issue date: 8 Sep 2022
Application
Filling date: 24 Feb 2022 Issue date: 8 Sep 2022
Grant
Filling date: 19 Dec 2019 Issue date: 30 Aug 2022
Application
Filling date: 23 Feb 2021 Issue date: 11 Aug 2022
Application
Filling date: 30 Nov 2021 Issue date: 4 Aug 2022
Application
Filling date: 29 Dec 2021 Issue date: 28 Jul 2022
Application
Filling date: 10 Jan 2022 Issue date: 21 Jul 2022
Application
Filling date: 2 Dec 2021 Issue date: 7 Jul 2022
Application
Filling date: 3 Dec 2021 Issue date: 30 Jun 2022
Application
Filling date: 3 Dec 2021 Issue date: 16 Jun 2022
Wednesday, 25 December 2024
zacks.com
Thursday, 19 December 2024
accesswire.com
Wednesday, 18 December 2024
accesswire.com
Tuesday, 17 December 2024
businesswire.com
accesswire.com
Monday, 16 December 2024
accesswire.com
Friday, 13 December 2024
accesswire.com
Thursday, 12 December 2024
accesswire.com
Wednesday, 11 December 2024
schaeffersresearch.com
accesswire.com
Tuesday, 10 December 2024
businesswire.com
accesswire.com
Monday, 9 December 2024
zacks.com
zacks.com
accesswire.com
Saturday, 7 December 2024
businesswire.com
Friday, 6 December 2024
businesswire.com
accesswire.com
Thursday, 5 December 2024
accesswire.com
Wednesday, 4 December 2024
accesswire.com
Friday, 29 November 2024
accesswire.com
Thursday, 28 November 2024
zacks.com
Tuesday, 26 November 2024
businesswire.com
accesswire.com
Monday, 25 November 2024
businesswire.com
accesswire.com
Thursday, 21 November 2024
accesswire.com
Tuesday, 19 November 2024
accesswire.com
zacks.com
investopedia.com
  • What's the price of Incyte stock today?

    One share of Incyte stock can currently be purchased for approximately $85.46.

  • When is Incyte's next earnings date?

    Unfortunately, Incyte's (INCY) next earnings date is currently unknown.

  • Does Incyte pay dividends?

    No, Incyte does not pay dividends.

  • How much money does Incyte make?

    Incyte has a market capitalization of 13.21B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 8.87% to 3.7B US dollars.

  • What is Incyte's stock symbol?

    Incyte Corporation is traded on the NASDAQ under the ticker symbol "INCY".

  • What is Incyte's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Incyte?

    Shares of Incyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Incyte's key executives?

    Incyte's management team includes the following people:

    • Mr. Herve Hoppenot Chairman, Pres & Chief Executive Officer(age: 65, pay: $2,550,000)
    • Ms. Christiana Stamoulis Executive Vice President & Chief Financial Officer(age: 54, pay: $989,390)
    • Dr. Steven H. Stein Executive Vice President & Chief Medical Officer(age: 58, pay: $967,800)
    • Dr. Vijay K. Iyengar M.D. Executive Vice President of Global Strategy & Corporation Devel.(age: 52, pay: $945,900)
    • Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA Executive Vice President & GM of North America(age: 67, pay: $833,630)
  • How many employees does Incyte have?

    As Jul 2024, Incyte employs 2,524 workers.

  • When Incyte went public?

    Incyte Corporation is publicly traded company for more then 31 years since IPO on 4 Nov 1993.

  • What is Incyte's official website?

    The official website for Incyte is incyte.com.

  • Where are Incyte's headquarters?

    Incyte is headquartered at 1801 Augustine Cut-Off, Wilmington, DE.

  • How can i contact Incyte?

    Incyte's mailing address is 1801 Augustine Cut-Off, Wilmington, DE and company can be reached via phone at +30 24986700.

  • What is Incyte stock forecast & price target?

    Based on 8 Wall Street analysts` predicted price targets for Incyte in the last 12 months, the avarage price target is $92.3. The average price target represents a 8.00% change from the last price of $85.46.

Incyte company profile:

Incyte Corporation

incyte.com
Exchange:

NASDAQ

Full time employees:

2,524

Industry:

Biotechnology

Sector:

Healthcare

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

1801 Augustine Cut-Off
Wilmington, DE 19803

CIK: 0000879169
ISIN: US45337C1027
CUSIP: 45337C102